This workflow is for a higher specialty trainee revising for the SCE in Medical Oncology who is using, or considering, Licence Medical. Licence Medical does publish a Medical Oncology SCE bank; used as one defined job — learning and gap-finding — with iatroX reserved for unseen measurement, it fits a first-pass-to-exit plan. Two limitations to name upfront: no MCQ bank reproduces the staging and toxicity judgement the exam leans on, and the ESMO Examination is a separate European exam, not the UK SCE — make sure any bank you buy targets the SCE blueprint.
Current-state box (last checked 21 July 2026)
| Attribute | Finding |
|---|---|
| Licence Medical SCE Medical Oncology bank | Listed on the Licence Medical catalogue (question-bank-details, Medical Oncology) |
| Live question count | Vendor-reported — not independently verifiable at the last check; verify on the product page |
| Access period / price | Vendor-reported — verify current options on the product page before paying |
| AI / adaptive features | None independently confirmed; iatroX supplies unseen-MCQ measurement and spaced retrieval — no proprietary-algorithm claim is made |
| Alternatives that also cover this SCE | StudyPRN Medical Oncology SCE (498 questions including a 100-question mock, £89 vendor-reported); BMJ OnExamination does not publish a Medical Oncology SCE product |
| ESMO caveat | The ESMO Examination is a distinct European exam; ESMO-branded banks target a different curriculum |
| Component addressed | Written best-of-five knowledge only; no bank reproduces consultant-supervised staging and toxicity management |
Do not invent the count or price — verify on the page, and check the bank is built for the UK SCE, not the ESMO syllabus.
Exam anchor
The SCE in Medical Oncology is two papers of 100 best-of-five questions each — 200 in total — three hours per paper, one day, computer-based, one mark per correct answer, no negative marking. Only the blueprint changes between specialties; this paper is built on the JRCPTB Medical Oncology curriculum and the mrcpuk.org blueprint, organised by tumour site alongside cross-cutting domains — staging, biomarkers, systemic therapy, toxicity and acute oncology, and supportive and palliative care. It is not the ESMO Examination; separate that official structure from any vendor's marketing.
Build a blueprint inventory and reserve an unseen pool
List the tumour sites and cross-cutting domains as rows and ring-fence a protected pool — perhaps a fifth of the bank plus a fresh iatroX block — untouched until the final fortnight. That reserved, unseen, timed set is your honest measurement instrument; the rest is for learning. The rarer sites are the ones candidates leave empty, so audit them explicitly.
First pass
Use topic-filtered blocks only where foundations are weak — the rarer sites, or toxicity grading — because topic filtering cues the domain and flatters the score. Where foundations are sound, start mixed so retrieval happens without the domain being handed to you. The first pass is for coverage and gap-finding, not a high percentage.
Review each miss with an error code
Do not transcribe the explanation. Tag each miss with one error code — knowledge gap, misread staging, misread biomarker, outdated therapy, or careless — and write one corrective action. A misread-staging error sends you to staging drills; an outdated-therapy error sends you to current NICE and SmPC/eMC sources, not the bank's paragraph. One code, one action, next question.
Transfer practice before repeating
When you miss an item, answer a new one testing the same principle before re-reading the original — a different tumour with the same biomarker logic, a different agent in the same class — so you confirm transfer rather than memorise the stem. iatroX supplies those fresh, unseen items; ordinary spaced retrieval, not a proprietary algorithm.
Switch to mixed timed blocks when floors are met
Once each domain clears a coverage floor and an accuracy floor on unseen items, switch to mixed, timed blocks even if the first pass is incomplete. Rehearsing exam conditions across the blueprint beats completing the last unseen fraction of a domain you already master.
Exit criteria
Exit on evidence, not completion. You are ready when coverage spans every tumour site and cross-cutting domain, unseen timed performance sits at target, pacing fits a shade under two minutes per item, retention holds on spaced re-tests, and your judgement calibrates against official material and consultant review. Completion percentage is not on the list.
Worked example: a seven-day plan around clinical work
Take a medical oncology registrar six weeks out, revising around a full clinical week. The defined job for Licence Medical this week is blueprint-coverage triage; iatroX supplies unseen transfer practice. No proprietary-algorithm claims are made.
- Day 1 — Map Licence Medical's Medical Oncology domains to the blueprint; reserve the unseen pool; confirm the bank targets the UK SCE, not ESMO.
- Day 2 — Two mixed blocks; error-code every miss; one corrective action each.
- Day 3 — Topic blocks only on the two weakest domains the map exposed (often the rarer sites and toxicity grading).
- Day 4 — Sit a fresh, timed iatroX block on the same domains; the delta between your Licence Medical score and your unseen score is your recognition-versus-recall signal.
- Day 5 — Re-test only the misses; convert each into a one-line rule from primary guidance.
- Day 6 — Consultant-checked staging and toxicity-management practice — the component no bank reproduces.
- Day 7 — Rest, then a short mixed unseen block to confirm the week held.
Your bank percentage is a study metric, not a mark forecast — read Your Q-Bank Percentage Is Not Your Exam Score before you read anything reassuring into it.
Reading your results
Read three numbers together, not one. Your coverage — the number of tumour sites and cross-cutting domains with real entries in your log — tells you whether you have met the breadth of the blueprint, and the rarer sites are where it usually falls short. Your fresh, unseen, timed score tells you what transfers to items you have not memorised. And the gap between that unseen score and your familiar Licence Medical percentage tells you how much of your confidence is recognition of a pool you have already seen. When coverage is complete, the unseen score sits at target, and the gap is small, you are ready to book; when the gap is wide, the corrective is the specific deficit the block exposed, not another pass. In Medical Oncology that deficit is most often the staging of a rarer site, biomarker-driven selection, or a toxicity or first-line regimen that has moved on — each closed with a consultant, the MDT and current guidance, not with more MCQs.
Decision checklist: continue, supplement, switch or stop
- Continue with Licence Medical while it keeps finding blueprint gaps and your unseen score is climbing.
- Supplement with iatroX unseen blocks the moment your Licence Medical score plateaus above your unseen score — that gap is memorised recognition.
- Switch or add StudyPRN if a tumour site stays uncovered or the systemic-therapy content feels dated — measured against the blueprint, not novelty; avoid ESMO-branded banks unless you are also sitting that exam.
- Stop grinding and pivot to consultant-checked staging and toxicity practice once your unseen blocks sit consistently at target.
Frequently asked questions
Is Licence Medical enough for SCE Medical Oncology on its own? It can be a strong single learning bank, since Licence Medical does list a Medical Oncology SCE bank, but one finite pool is rarely enough alone because it trains recognition of its own items and its systemic-therapy content freezes at its last edit — a real risk in a fast-moving field. Pair it with a separate unseen layer and consultant-checked staging and toxicity practice, verify its live count and price on the product page, and confirm it targets the UK SCE rather than the ESMO Examination.
Which SCE Medical Oncology component does Licence Medical not reproduce well? Staging from described data and the management of treatment toxicity and acute oncology are the components no MCQ bank rehearses well, because both are protocol-driven, time-critical judgements rather than single-fact selections. Build staging with anonymised cases reviewed in an MDT or by a consultant, and toxicity management from current acute-oncology and immune-related-adverse-event guidance.
How many Licence Medical questions should I complete per day for SCE Medical Oncology? Aim for distinct-concept coverage rather than raw volume — roughly 40 to 60 new items a day is sustainable around clinical work, each logged against a tumour site or cross-cutting domain. Because the live count is vendor-reported and not independently verified here, do not make "finishing the bank" the goal; make covering the blueprint the goal, and move to unseen items once recognition of a fixed set outpaces unseen performance.
When should I stop using Licence Medical and move to mixed mocks? Move to mixed, timed mocks when every domain clears its coverage and accuracy floor on unseen items, even if the first pass is incomplete. If your Licence Medical score is high but your unseen-block score lags, that gap is recognition, not readiness, and it signals a switch to mixed practice rather than another pass through the same pool.
How should I combine Licence Medical with iatroX without duplicating practice? Give each one job: Licence Medical to learn and surface gaps, iatroX purely as the unseen-measurement layer that confirms transfer, following the two-Q-bank rule. Never answer the same item in both; when a Licence Medical question teaches a concept, test that concept on a fresh iatroX item so you measure transfer rather than memory of a stem.
Editorial notes and references
Written by Dr Kolawole Tytler, NHS GP and founder of iatroX. Last checked 21 July 2026. Vendor-reported figures (question counts, prices, access periods) change without notice and are labelled as such throughout; Licence Medical's live Medical Oncology count and price were not independently verifiable at the last check and should be confirmed on the product page. Disclosure: iatroX operates a competing question resource, confined here to cross-specialty UK/MRCP-level knowledge and unseen-MCQ measurement — the job Licence Medical's bank does not claim; iatroX is not a specialty-specific SCE Medical Oncology bank and does not reproduce consultant-supervised staging or toxicity management. Corrections are welcome via the feedback route on iatrox.com.
References: The Federation — SCE in Medical Oncology; Licence Medical — Medical Oncology; StudyPRN Medical Oncology SCE; iatroX comparison hub, the two-Q-bank rule, what MCQ banks cannot prepare you for in SCE Medical Oncology and the SCE knowledge bank.